# IMC-001

Source: https://onco.cc/drugs/imc-001/  
OnCo record `imc-001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IMC-001 is an experimental monoclonal antibody from ImmuneOncia Therapeutics, in phase 2 trials for extranodal NK/T-cell lymphoma, nasal type, TMB-high solid tumours and resectable gastric, oesophageal and liver cancer.

## Summary

IMC-001 (STI-3031) is a monoclonal antibody (fully human IgG1) from ImmuneOncia Therapeutics, with Sorrento Therapeutics as registered STI-3031 (other name IMC-001) trials. A fully human IgG1 antibody against PD-L1 that blocks PD-1/PD-L1 binding and also triggers antibody-dependent cellular cytotoxicity by NK cells. Its furthest stage is phase 2, for extranodal NK/T-cell lymphoma, nasal type, TMB-high solid tumours and resectable gastric, oesophageal and liver cancer (investigator neoadjuvant study). ClinicalTrials.gov registers it in 5 studies linked below. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: STI-3031
- Tags: pipeline; ctgov-ingest
- Code: IMC-001
- Modality: Monoclonal antibody (fully human IgG1)
- Mechanism: A fully human IgG1 antibody against PD-L1 that blocks PD-1/PD-L1 binding and also triggers antibody-dependent cellular cytotoxicity by NK cells.

## Sources

- ImmuneOncia Therapeutics: immuneoncia.com: https://www.immuneoncia.com/en/m24.php
- ImmuneOncia Therapeutics: immuneoncia.com: https://www.immuneoncia.com/en/m23.php
- ImmuneOncia Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT04414163
- ClinicalTrials.gov: trials of IMC-001: https://clinicaltrials.gov/search?intr=IMC-001

## Connected records

- cancers: [Extranodal NK/T-cell lymphoma](https://onco.cc/cancers/extranodal-nk-t-cell-lymphoma/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [ImmuneOncia Therapeutics](https://onco.cc/companies/immuneoncia-therapeutics/)
- trials: [A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor](https://onco.cc/trials/nct06365840/), [A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type](https://onco.cc/trials/nct04414163/), [Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors](https://onco.cc/trials/nct03644056/), [Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study](https://onco.cc/trials/nct05393713/), [Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers](https://onco.cc/trials/nct04196465/)

---
JSON: https://onco.cc/api/v1/entities/imc-001.json